ONGOING STRATEGIC REVIEW HAS RESULTED IN DIVESTITURES GENERATING SIGNIFICANT PROCEEDS, SIMPLIFYING MATTHEWS' BUSINESS MIX AND STRENGTHENING ITS BALANCE SHEET CONFIRMS RECEIPT OF ANOTHER NOTICE OF DIRECTOR NOMINATIONS FROM BARINGTON, LESS THAN ONE YEAR AFTER BARINGTON UNSUCCESSFULLY RAN A PROXY CONTEST AT THE 2025 ANNUAL MEETING MATTHEWS' SHAREHOLDER PROPOSALS WILL INCLUDE BOARD DECLASSIFICATION AND THE ADOPTION OF MAJORITY VOTING AMONG OTHER CHANGES DESIRED BY INVESTORS SHAREHOLDERS NOT REQUIRED TO TAKE ANY ACTION AT THIS TIME PITTSBURGH , DEC. 7, 2025 /PRNEWSWIRE/ -- MATTHEWS INTERNATIONAL CORPORATION (NASDAQ GSM: MATW) ("MATTHEWS" OR THE "COMPANY") TODAY ISSUED THE FOLLOWING STATEMENT UPDATING SHAREHOLDERS ON THE COMPANY'S ONGOING STRATEGIC INITIATIVES AND CONFIRMING RECEIPT OF ANOTHER NOTICE FROM BARINGTON CAPITAL L.P.'S ("BARINGTON") OF ITS INTENT TO NOMINATE DIRECTORS FOR ELECTION AT A SECOND CONSECUTIVE ANNUAL MEETING OF SHAREHOLDERS: MATTHEWS BOARD AND MANAGEMENT CONTINUE TO TAKE DECISIVE ACTIONS TO ADVANCE STRATEGIC INITIATIVES IN NOVEMBER 2024, WE ANNOUNCED THAT THE BOARD HAD ENGAGED J.P.
MATW
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS LIFE SCIENCES GROUP, INC. (NASDAQ: SLS) (“SELLAS'' OR THE “COMPANY”), A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL THERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS, TODAY ANNOUNCED THAT CLINICAL DATA FROM ITS ONGOING PHASE 2 STUDY OF SLS009, A HIGHLY SELECTIVE CDK9 INHIBITOR, IN COMBINATION WITH AZACITIDINE (AZA) AND VENETOCLAX (VEN) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYSPLASTIC SYNDROME-RELATED CHANGES (AML-MR) AFTER PRIOR VEN-BASED TREATMENT WERE PRESENTED TODAY AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION, BEING HELD DECEMBER 6 – 9, 2025, IN ORLANDO, FLORIDA.
SLS
• Dec. 7, 2025
NEW YORK , DEC. 7, 2025 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF JAMES HARDIE INDUSTRIES PLC (NYSE: JHX) BETWEEN MAY 20, 2025 THROUGH AUGUST 18, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 23, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED JAMES HARDIE COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
JHX
• Dec. 7, 2025
LOS ANGELES--(BUSINESS WIRE)--NATIONAL FUEL GAS COMPANY INVESTIGATED FOR BREACHES OF FIDUCIARY DUTY - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS – NFG.
NFG
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF FREEPORT-MCMORAN INC. (NYSE: FCX) BETWEEN FEBRUARY 15, 2022 AND SEPTEMBER 24, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 12, 2026 LEAD PLAINTIFF DEADLINE IN THE SECURITIES CLASS ACTION FIRST FILED BY THE FIRM. SO WHAT: IF YOU PURCHASED FREEPORT-MCMORAN SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
TOP
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF SKYE BIOSCIENCE, INC. (NASDAQ: SKYE) BETWEEN NOVEMBER 4, 2024 AND OCTOBER 3, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 16, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED SKYE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
SKYE
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES AND SELLERS OF PUT OPTIONS OF SPROUTS FARMERS MARKET, INC. (NASDAQ: SFM) BETWEEN JUNE 4, 2025 AND OCTOBER 29, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"). IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURT NO LATER THAN JANUARY 26, 2026.
SFM
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF DEFI TECHNOLOGIES, INC. (NASDAQ: DEFT) BETWEEN MAY 12, 2025 AND NOVEMBER 14, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"). A CLASS ACTION LAWSUIT HAS ALREADY BEEN FILED.
DEFTF
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OR SELLERS OF COMMON STOCK OF CEPTON, INC. (NASDAQ: CPTN) BETWEEN JULY 29, 2024 AND JANUARY 6, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 8, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED OR SOLD CEPTON COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
CPTN
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF BLUE OWL CAPITAL INC. (NYSE: OWL) BETWEEN FEBRUARY 6, 2025 AND NOVEMBER 16, 2025. A CLASS ACTION LAWSUIT HAS ALREADY BEEN FILED.
OWL
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES A CLASS ACTION LAWSUIT ON BEHALF OF PURCHASERS OF SECURITIES OF ALEXANDRIA REAL ESTATE EQUITIES, INC. (NYSE: ARE) BETWEEN JANUARY 27, 2025 AND OCTOBER 27, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"). A CLASS ACTION LAWSUIT HAS ALREADY BEEN FILED.
ARE
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF PERRIGO COMPANY PLC (NYSE: PRGO) BETWEEN FEBRUARY 27, 2023 AND NOVEMBER 4, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 16, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED PERRIGO SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
PRGO
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF INSPIRE MEDICAL SYSTEMS, INC. (NYSE: INSP) BETWEEN AUGUST 6, 2024 AND AUGUST 4, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 5, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED INSPIRE MEDICAL COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
INSP
• Dec. 7, 2025
INTERSECTION OF 28.9M AT 2.5G/T AUEQ JUST 200M FROM SURFACE OFFERS POTENTIAL FOR ADDITIONAL RESOURCE GROWTH; FOLLOW-UP DRILLING TO START NEXT WEEK INTERSECTION OF 28.9M AT 2.5G/T AUEQ JUST 200M FROM SURFACE OFFERS POTENTIAL FOR ADDITIONAL RESOURCE GROWTH; FOLLOW-UP DRILLING TO START NEXT WEEK
CYGGF
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF TELIX PHARMACEUTICALS LTD. (NASDAQ: TLX) BETWEEN FEBRUARY 21, 2025 AND AUGUST 28, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 9, 2026 LEAD PLAINTIFF DEADLINE IN THE SECURITIES CLASS ACTION FIRST FILED BY THE FIRM.
LAW
• Dec. 7, 2025
--(BUSINESS WIRE)--GARTNER WILL EXPLORE “AUTONOMOUS FINANCE: BUILDING RESILIENT, AI-DRIVEN, AND VALUE-CENTRIC ENTERPRISES” DURING THE GARTNER FINANCE SYMPOSIUM/XPO.
IT
• Dec. 7, 2025
NEW YORK , DEC. 7, 2025 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF AGILON HEALTH, INC. (NYSE: AGL) RESULTING FROM ALLEGATIONS THAT AGILON HEALTH MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC.
AGL
• Dec. 7, 2025
ALL THREE DOSE GROUPS (50 MG, 100 MG AND 200 MG) SHOWED IMPRESSIVE MONOTHERAPY EFFICACY, WITH VGPR+ (VERY GOOD PARTIAL RESPONSE OR BETTER) OF ≥70% DESPITE LIMITED FOLLOW-UP; EVIDENCE SHOWS THAT THESE RESPONSES ARE EXPECTED TO DEEPEN OVER TIME
REGN
• Dec. 7, 2025
SOUTH SAN FRANCISCO, CALIF., DEC. 07, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED NEW CLINICAL AND TRANSLATIONAL DATA FROM THE ONGOING CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL, ALSO KNOWN AS LYL314) IN PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL), WHICH WERE PRESENTED TODAY IN TWO ORAL PRESENTATIONS AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION. AS OF THE DATA CUTOFF DATE OF SEPTEMBER 5, 2025, RONDE-CEL CONTINUED TO DEMONSTRATE ROBUST CLINICAL RESPONSES WITH A MANAGEABLE SAFETY PROFILE APPROPRIATE FOR OUTPATIENT ADMINISTRATION. A 93% OVERALL RESPONSE RATE, A 76% COMPLETE RESPONSE RATE, AND MEDIAN PROGRESSION-FREE SURVIVAL OF 18 MONTHS WERE REPORTED FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LBCL IN THE THIRD- OR LATER-LINE (3L+) SETTING. PATIENTS EVALUATED IN THE SECOND-LINE (2L) SETTING (94% WITH DIFFICULT-TO-TREAT PRIMARY REFRACTORY DISEASE) ACHIEVED AN 83% OVERALL RESPONSE RATE AND A 61% COMPLETE RESPONSE RATE, AND 70% OF PATIENTS WITH A COMPLETE RESPONSE REMAINED IN COMPLETE RESPONSE AT 6 MONTHS OR LONGER.
ASH
• Dec. 7, 2025
IN ADDITION TO MEETING THE PRIMARY ENDPOINT OF NON-INFERIORITY FOR OVERALL RESPONSE RATE (ORR) IN THE BRUIN CLL-314 STUDY, PIRTOBRUTINIB ACHIEVED A NUMERICALLY HIGHER ORR OF 87.0% COMPARED TO 78.5% FOR IBRUTINIB IN THE INTENT-TO-TREAT (ITT) POPULATION PROGRESSION-FREE SURVIVAL DATA WERE IMMATURE BUT TRENDED IN FAVOR OF PIRTOBRUTINIB WITH A 43% REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH IN THE ITT POPULATION, AND THE TREATMENT-NAÏVE SUBGROUP, WHICH HAD THE LONGEST FOLLOW UP, SHOWED A 76% REDUCTION THESE DATA WILL BE SIMULTANEOUSLY PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY AND PRESENTED AT THE 2025 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING AND EXPOSITION, AS WELL AS FEATURED AS PART OF THE MEETING'S PRESS PROGRAM INDIANAPOLIS , DEC. 7, 2025 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED RESULTS FROM THE PHASE 3 BRUIN CLL-314 CLINICAL TRIAL EVALUATING JAYPIRCA (PIRTOBRUTINIB), A NON-COVALENT (REVERSIBLE) BRUTON TYROSINE KINASE (BTK) INHIBITOR, VERSUS IMBRUVICA (IBRUTINIB), A COVALENT BTK INHIBITOR, IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO WERE TREATMENT-NAÏVE OR WERE BTK INHIBITOR-NAÏVE. PIRTOBRUTINIB MET ITS PRIMARY ENDPOINT OF NON-INFERIORITY ON OVERALL RESPONSE RATE (ORR) COMPARED TO IBRUTINIB (87.0% [95% CI, 82.90-90.44] VERSUS 78.5% [95% CI, 73.73-82.85]; P1% OF PATIENTS INCLUDED PNEUMONIA.
LLY
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 15, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED MOONLAKE COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
MLTX
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF STUBHUB HOLDINGS, INC. (NYSE: STUB) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT ISSUED IN CONNECTION WITH STUBHUB'S SEPTEMBER 2025 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT JANUARY 23, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED STUBHUB COMMON STOCK YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
STUB
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF MAREX GROUP PLC (NASDAQ: MRX) BETWEEN MAY 16, 2024 AND AUGUST 5, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 8, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED MAREX SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
MRX
• Dec. 7, 2025
CAMBRIDGE, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- WAVE LIFE SCIENCES LTD.
WVE
• Dec. 7, 2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF EAGLE PHARMACEUTICALS, INC. (OTCPK: EGRX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN EAGLE STOCK AND ARE A LONG-TERM SHAREHOLDER, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO LEARN MORE ABOUT YO.
EGRX
• Dec. 7, 2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF LIFECORE BIOMEDICAL, INC. (NASDAQ: LFCR) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN LIFECORE STOCK AND ARE A LONG-TERM SHAREHOLDER, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO LEARN MORE ABOUT.
LFCR
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF STRIDE, INC. (NYSE: LRN) BETWEEN OCTOBER 22, 2024 AND OCTOBER 28, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 12, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED STRIDE SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
LRN
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF CARMAX, INC. (NYSE: KMX) BETWEEN JUNE 20, 2025 AND NOVEMBER 5, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT JANUARY 2, 2026 LEAD PLAINTIFF DEADLINE IN THE SECURITIES CLASS ACTION FIRST FILED BY THE FIRM. SO WHAT: IF YOU PURCHASED CARMAX SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
LAW
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF PRIMO WATER CORPORATION (NYSE: PRMW) BETWEEN JUNE 17, 2024 AND NOVEMBER 8, 2024, BOTH DATES INCLUSIVE, AND/OR (II) PURCHASERS OF COMMON STOCK OF PRIMO BRANDS CORPORATION (NYSE: PRMB) BETWEEN NOVEMBER 11, 2024 AND NOVEMBER 6, 2025 (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 12, 2026 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED PRIMO BRANDS SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
PRMB
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF JAYUD GLOBAL LOGISTICS LTD. (NASDAQ: JYD) BETWEEN APRIL 21, 2023 AND APRIL 30, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT JANUARY 20, 2026 LEAD PLAINTIFF DEADLINE.
LAW
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF AVANTOR, INC. (NYSE: AVTR) BETWEEN MARCH 5, 2024 AND OCTOBER 28, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 29, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED AVANTOR COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
AVTR
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF DEXCOM, INC. (NASDAQ: DXCM) BETWEEN JULY 26, 2024 AND SEPTEMBER 17, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD") OF THE IMPORTANT DECEMBER 29, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED DEXCOM SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
DXCM
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF TANDEM DIABETES CARE, INC. (NASDAQ: TNDM) RESULTING FROM ALLEGATIONS THAT TANDEM DIABETES CARE MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED TANDEM DIABETES SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
LAW
• Dec. 7, 2025
SAN FRANCISCO , DEC. 7, 2025 /PRNEWSWIRE/ -- PROLOGIS, INC. (NYSE: PLD) ANNOUNCED TODAY THAT PROLOGIS, L.P. WILL REDEEM ALL OF ITS OUTSTANDING 3.00% NOTES DUE JUNE 2, 2026 (CUSIP NUMBER 74340XBB6, ISIN XS1072516690 AND COMMON CODE 107251669, THE "BONDS"), FOLLOWING WHICH THE BONDS WILL BE DELISTED FROM THE NEW YORK STOCK EXCHANGE.
PLD
• Dec. 7, 2025
MIGUEL HIDALGO, MEXICO CITY--(NEWSFILE CORP. - DECEMBER 7, 2025) - MAGUEN GROUP, A LEADING MEXICAN PRIVATE SECURITY COMPANY WITH OVER
• Dec. 7, 2025
AUSTIN, TEXAS--(NEWSFILE CORP. - DECEMBER 7, 2025) - STICKYHIVE TODAY ANNOUNCED THE LAUNCH OF THE FIRST COMPREHENSIVE AI COMMUNITY MANAGEMENT
• Dec. 7, 2025
TRIPOLI, LIBYA--(NEWSFILE CORP. - DECEMBER 7, 2025) - LIBYA STEPPED FIRMLY BACK ONTO THE REGIONAL ENERGY STAGE TODAY WITH THE
• Dec. 7, 2025
SAN FRANCISCO, CALIFORNIA--(NEWSFILE CORP. - DECEMBER 7, 2025) - INTERVIEW CODER TODAY ANNOUNCED THE LAUNCH OF INTERVIEW CODER 2.0, A
• Dec. 7, 2025
- 94% OF PATIENTS (51 OF 54) REMAINED FREE FROM THE BURDEN OF CONTINUOUS PROPHYLAXIS TREATMENT THROUGH FIVE YEARS FOLLOWING A SINGLE INFUSION OF HEMGENIX, DEMONSTRATING SUSTAINED THERAPEUTIC BENEFIT- AT YEAR FIVE, MEAN FACTOR IX ACTIVITY LEVELS REMAINED STRONG AT 36.1% AND HEMGENIX CONTINUED TO DEMONSTRATE A FAVORABLE SAFETY PROFILE, REINFORCING ITS DURABLE EFFICACY- MORE THAN 75 INDIVIDUALS ACROSS EIGHT COUNTRIES HAVE RECEIVED HEMGENIX IN REAL-WORLD SETTINGS, REFLECTING GROWING GLOBAL ADOPTION KING OF PRUSSIA, PA. , DEC. 7, 2025 /PRNEWSWIRE/ -- GLOBAL BIOPHARMA LEADER CSL (ASX:CSL; USOTC:CSLLY) TODAY ANNOUNCED FIVE-YEAR (60-MONTH) RESULTS FROM THE PIVOTAL PHASE 3 HOPE-B STUDY, CONFIRMING THE LONG-TERM DURABILITY AND SAFETY OF A ONE-TIME INFUSION OF HEMGENIX® (ETRANACOGENE DEZAPARVOVEC-DRLB) IN ADULTS LIVING WITH HEMOPHILIA B.
QURE
• Dec. 7, 2025
FRANKLIN, IN / ACCESS NEWSWIRE / DECEMBER 7, 2025 / IBC ADVANCED ALLOYS CORP. ("IBC" OR THE "COMPANY") (TSX-V:IB)(OTCQB:IAALF) ANNOUNCES THE RESULTS OF ITS 2025 ANNUAL GENERAL MEETING (THE "MEETING"), HELD ON DECEMBER 5, 2024, IN CENTENNIAL, CO. AT THE MEETING, THE SHAREHOLDERS RE-ELECTED TO THE BOARD OF DIRECTORS BY ORDINARY RESOLUTION, MARK A.
IAALF
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- ATTORNEY ADVERTISING -- BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, A NATIONALLY RECOGNIZED LAW FIRM, NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST MAREX GROUP PLC (“MAREX” OR “THE COMPANY”) (NASDAQ: MRX) AND CERTAIN OF ITS OFFICERS.
MRX
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- ATTORNEY ADVERTISING -- BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, A NATIONALLY RECOGNIZED LAW FIRM, NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST WPP PLC (“WPP” OR “THE COMPANY”) (NYSE: WPP) AND CERTAIN OF ITS OFFICERS.
WPP
• Dec. 7, 2025
NEW YORK , DEC. 7, 2025 /PRNEWSWIRE/ -- ATTORNEY ADVERTISING -- BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, A NATIONALLY RECOGNIZED LAW FIRM, NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST BITDEER TECHNOLOGIES GROUP ("BITDEER" OR "THE COMPANY") (NASDAQ: BTDR) AND CERTAIN OF ITS OFFICERS. CLASS DEFINITION THIS LAWSUIT SEEKS TO RECOVER DAMAGES AGAINST DEFENDANTS FOR ALLEGED VIOLATIONS OF THE FEDERAL SECURITIES LAWS ON BEHALF OF ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED BITDEER SECURITIES BETWEEN JUNE 6, 2024 AND NOVEMBER 10, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD").
BTDR
• Dec. 7, 2025
FARUQI AND FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN THE WILDERMUTH FUND TO
• Dec. 7, 2025
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - DECEMBER 7, 2025) - GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF SHAREHOLDERS OF LANTHEUS HOLDINGS, INC. (NASDAQ: LNTH). THE INVESTIGATION CONCERNS WHETHER CERTAIN OFFICERS AND DIRECTORS BREACHED THE FIDUCIARY DUTIES THEY OWED TO THE COMPANY.
LNTH
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF AMERICAN DEPOSITARY SHARES ("ADS" OR "ADSS") OF WPP PLC (NYSE: WPP) BETWEEN FEBRUARY 27, 2025 AND JULY 8, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 8, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED WPP ADSS DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
WPP
• Dec. 7, 2025
WALTHAM, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THAT IT PLANS TO ANNOUNCE TOPLINE CLINICAL RESULTS FROM THE REGISTRATIONAL EXPANSION COHORT (REC) OF THE PHASE 1/2 DELIVER TRIAL OF ZELECIMENT ROSTUDIRSEN (Z-ROSTUDIRSEN, ALSO KNOWN AS DYNE-251) ON DECEMBER 8, 2025, AND TO HOST A WEBCAST AT 8:00 A.M. ET. THE COMPANY INTENDS TO ISSUE A PRESS RELEASE PRIOR TO THE START OF THE EVENT.
DYN
• Dec. 7, 2025
NEW YORK , DEC. 7, 2025 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF SECURITIES OF MAREX GROUP PLC (NASDAQ: MRX) BETWEEN MAY 16, 2024 AND AUGUST 5, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 8, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED MAREX SECURITIES DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
MRX
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ALVOTECH (NASDAQ: ALVO) RESULTING FROM ALLEGATIONS THAT ALVOTECH MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ALVOTECH SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
ALVO
• Dec. 7, 2025
RADNOR, PA., DEC. 07, 2025 (GLOBE NEWSWIRE) -- THE LAW FIRM OF KESSLER TOPAZ MELTZER & CHECK, LLP (WWW.KTMC.COM) INFORMS INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST STUBHUB HOLDINGS, INC. (“STUBHUB”) (NYSE: STUB) ON BEHALF OF THOSE WHO PURCHASED OR OTHERWISE ACQUIRED STUBHUB COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE “OFFERING DOCUMENTS”) ISSUED IN CONNECTION WITH STUBHUB'S SEPTEMBER 2025 INITIAL PUBLIC OFFERING. THE LEAD PLAINTIFF DEADLINE IS JANUARY 23, 2026.
STUB
• Dec. 7, 2025
AUSTIN, DEC. 07, 2025 (GLOBE NEWSWIRE) -- THE HYPER CONVERGED INFRASTRUCTURE MARKET SIZE WAS VALUED AT USD 16. 16 BILLION IN 2025 AND IS EXPECTED TO REACH USD 84. 72 BILLION BY 2033, GROWING AT A CAGR OF 23. 01% OVER 2026-2033.
• Dec. 7, 2025
AUSTIN, DEC. 07, 2025 (GLOBE NEWSWIRE) -- THE DECISION INTELLIGENCE MARKET WAS VALUED AT 18. 08 BILLION IN 2025E AND IS EXPECTED TO REACH USD 74. 23 BILLION BY 2033, GROWING AT A CAGR OF 19. 31% OVER 2026-2033.
• Dec. 7, 2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ASH2025--INCYTE'S FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, INCA033989, GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA.
INCY
• Dec. 7, 2025
WILMINGTON, DEL.--(BUSINESS WIRE)---- $INCY #ASH2025--INCYTE ANNOUNCES NEW POSITIVE DATA FOR INCA033989, ITS FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, IN PATIENTS WITH MF PRESENTED AT ASH 2025.
INCY
• Dec. 7, 2025
AUSTIN, DEC. 07, 2025 (GLOBE NEWSWIRE) -- THE DDOS PROTECTION AND MITIGATION MARKET SIZE WAS VALUED AT USD 5. 84 BILLION IN 2025E AND IS EXPECTED TO REACH USD 17. 15 BILLION BY 2033, GROWING AT A CAGR OF 14. 42% OVER THE FORECAST PERIOD.
• Dec. 7, 2025
HERZLIYA, ISRAEL, DEC. 07, 2025 (GLOBE NEWSWIRE) -- NAYAX LTD. (NASDAQ: NYAX; TASE: NYAX) (THE “COMPANY”), A GLOBAL COMMERCE PAYMENTS AND LOYALTY PLATFORM DESIGNED TO HELP MERCHANTS SCALE THEIR BUSINESS, ANNOUNCED TODAY THAT IT IS CONSIDERING AN OFFERING BY WAY OF AN EXPANSION OF ITS EXISTING SERIES A NOTES AND SERIES 1 WARRANTS, WITH SUCH OFFERING TO BE MADE TO THE PUBLIC IN ISRAEL ONLY.
NYAX
• Dec. 7, 2025
R289 CONTINUES TO BE GENERALLY WELL TOLERATED AND AT DOSES OF ≥500 MG QD PRELIMINARY EFFICACY WAS OBSERVED IN ELDERLY, HEAVILY PRE-TREATED LOWER-RISK MDS PATIENTS RBC-TI WAS ACHIEVED BY 33% (6/18) OF EVALUABLE TRANSFUSION DEPENDENT PATIENTS RECEIVING R289 DOSES ≥500 MG QD, INCLUDING 40% (2/5) IN THE 500 MG BID DOSE GROUP SOUTH SAN FRANCISCO, CALIF. , DEC. 7, 2025 /PRNEWSWIRE/ -- RIGEL PHARMACEUTICALS, INC. (NASDAQ: RIGL), A COMMERCIAL STAGE BIOTECHNOLOGY COMPANY FOCUSED ON HEMATOLOGIC DISORDERS AND CANCER, TODAY ANNOUNCED UPDATED DATA FROM ITS ONGOING PHASE 1B STUDY EVALUATING R2891, AN ORAL PRODRUG OF R835, A POTENT AND SELECTIVE DUAL INHIBITOR OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES 1 AND 4 (IRAK1/4), IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LOWER-RISK MYELODYSPLASTIC SYNDROME (MDS).
ASH
• Dec. 7, 2025
AUSTIN, TEXAS, DEC. 07, 2025 (GLOBE NEWSWIRE) -- ANTIBODY DISCOVERY MARKET SIZE AND GROWTH ANALYSIS: ACCORDING TO SNS INSIDER, THE ANTIBODY DISCOVERY MARKET SIZE WAS VALUED AT USD 8. 42 BILLION IN 2024 AND IS PROJECTED TO REACH USD 17. 68 BILLION BY 2032, GROWING AT A CAGR OF 9.
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ATYR TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ATYR BETWEEN JANUARY 16, 2025 AND SEPTEMBER 12, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ATYR PHARMA, INC. ("ATYR" OR THE "COMPANY") (NASDAQ: ATYR) AND REMINDS INVESTORS OF THE DECEMBER 8, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
ATYR
• Dec. 7, 2025
NEW YORK , DEC. 7, 2025 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF COMMON STOCK OF MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) BETWEEN MARCH 10, 2024 AND SEPTEMBER 29, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), OF THE IMPORTANT DECEMBER 15, 2025 LEAD PLAINTIFF DEADLINE. SO WHAT: IF YOU PURCHASED MOONLAKE COMMON STOCK DURING THE CLASS PERIOD YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT.
MLTX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN PRIMO BRANDS TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES: (A) THE COMMON STOCK OF PRIMO WATER BETWEEN JUNE 17, 2024 THROUGH NOVEMBER 8, 2024, INCLUSIVE, AND/OR (B) THE COMMON STOCK OF PRIMO BRANDS BETWEEN NOVEMBER 11, 2024 THROUGH NOVEMBER 6, 2025, INCLUSIVE (COLLECTIVELY, THE "CLASS PERIOD") AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST PRIMO BRANDS CORPORATION ("PRIMO BRANDS" OR THE "COMPANY") (NYSE: PRMB) AND REMINDS INVESTORS OF THE JANUARY 12, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
PRMB
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN DEFI TECHNOLOGIES TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN DEFI TECHNOLOGIES BETWEEN MAY 12, 2025 AND NOVEMBER 14, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST DEFI TECHNOLOGIES INC. ("DEFI TECHNOLOGIES" OR THE "COMPANY") (NASDAQ: DEFT) AND REMINDS INVESTORS OF THE JANUARY 30, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
DEFTF
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN FIREFLY AEROSPACE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR OTHERWISE ACQUIRED: (A) FIREFLY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE OFFERING DOCUMENTS (DEFINED BELOW) ISSUED IN CONNECTION WITH THE COMPANY'S INITIAL PUBLIC OFFERING CONDUCTED ON OR ABOUT AUGUST 7, 2025 (THE "IPO" OR "OFFERING"); AND/OR (B) FIREFLY SECURITIES BETWEEN AUGUST 7, 2025 AND SEPTEMBER 29, 2025, BOTH DATES INCLUSIVE (THE "CLASS PERIOD") AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST FIREFLY AEROSPACE INC. ("FIREFLY" OR THE "COMPANY") (NASDAQ: FLY) AND REMINDS INVESTORS OF THE JANUARY 12, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
FLY
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN STUBHUB TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR OTHERWISE ACQUIRED STOCK OF STUBHUB PURSUANT AND/OR TRACEABLE TO STUBHUB'S REGISTRATION STATEMENT FOR THE INITIAL PUBLIC OFFERING HELD ON OR ABOUT SEPTEMBER 17, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST STUBHUB HOLDINGS, INC. ("STUBHUB" OR THE "COMPANY") (NYSE: STUB) AND REMINDS INVESTORS OF THE JANUARY 23, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
STUB
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN INSPIRE MEDICAL TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN INSPIRE MEDICAL BETWEEN AUGUST 6, 2024 AND AUGUST 4, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST INSPIRE MEDICAL SYSTEMS, INC. ("INSPIRE MEDICAL" OR THE "COMPANY") (NYSE: INSP) AND REMINDS INVESTORS OF THE JANUARY 5, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
INSP
• Dec. 7, 2025
AUSTIN, TEXAS, DEC. 07, 2025 (GLOBE NEWSWIRE) -- AUTISM SPECTRUM DISORDER MARKET SIZE AND GROWTH ANALYSIS ACCORDING TO SNS INSIDER, THE AUTISM SPECTRUM DISORDER MARKET SIZE IS ESTIMATED AT USD 2. 06 BILLION IN 2025 AND IS EXPECTED TO REACH USD 4.
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN CARMAX TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES IN CARMAX BETWEEN JUNE 20, 2025 AND SEPTEMBER 24, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST CARMAX, INC. ("CARMAX" OR THE "COMPANY") (NYSE: KMX) AND REMINDS INVESTORS OF THE JANUARY 2, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
KMX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN WPP TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN WPP BETWEEN FEBRUARY 27, 2025 AND JULY 8, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST WPP PLC ("WPP" OR THE "COMPANY") (NYSE: WPP) AND REMINDS INVESTORS OF THE DECEMBER 8, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
WPP
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN FREEPORT-MCMORAN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN FREEPORT BETWEEN FEBRUARY 15, 2022 AND SEPTEMBER 24, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST FREEPORT-MCMORAN INC. ("FREEPORT" OR THE "COMPANY") (NYSE: FCX) AND REMINDS INVESTORS OF THE JANUARY 12, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
FCX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN MAREX TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN MAREX BETWEEN MAY 16, 2024 AND AUGUST 5, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST MAREX GROUP PLC ("MAREX" OR THE "COMPANY") (NASDAQ: MRX) AND REMINDS INVESTORS OF THE DECEMBER 8, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
MRX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED SIGNIFICANT LOSSES IN NIDEC TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED SIGNIFICANT LOSSES IN NIDEC STOCK OR OPTIONS AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST NIDEC CORPORATION ("NIDEC" OR THE "COMPANY") (OTC: NJDCY).
NJDCY
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED SIGNIFICANT LOSSES IN TVARDI TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED SIGNIFICANT LOSSES IN TVARDI STOCK OR OPTIONS AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST TVARDI THERAPEUTICS, INC. ("TVARDI" OR THE "COMPANY") (NASDAQ: TVRD).
TVRD
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN TELIX TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN TELIX BETWEEN FEBRUARY 21, 2025 AND AUGUST 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST TELIX PHARMACEUTICALS LIMITED ("TELIX" OR THE "COMPANY") (NASDAQ: TLX) AND REMINDS INVESTORS OF THE JANUARY 9, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
TLX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN BITDEER TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN BITDEER BETWEEN JUNE 6, 2024 AND NOVEMBER 10, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST BITDEER TECHNOLOGIES GROUP ("BITDEER" OR THE "COMPANY") (NASDAQ: BTDR) AND REMINDS INVESTORS OF THE FEBRUARY 2, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
BTDR
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN JAMES HARDIE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN JAMES HARDIE BETWEEN MAY 20, 2025 AND AUGUST 18, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST JAMES HARDIE INDUSTRIES PLC ("JAMES HARDIE" OR THE "COMPANY") (NYSE: JHX) AND REMINDS INVESTORS OF THE DECEMBER 23, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
JHX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SKYE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SKYE BETWEEN NOVEMBER 4, 2024 AND OCTOBER 3, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SKYE BIOSCIENCES, INC. ("SKYE" OR THE "COMPANY") (NASDAQ: SKYE) AND REMINDS INVESTORS OF THE JANUARY 16, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
SKYE
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED IN AVANTOR TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN AVANTOR BETWEEN MARCH 5, 2024 AND OCTOBER 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST AVANTOR, INC. ("AVANTOR" OR THE "COMPANY") (NYSE: AVTR) AND REMINDS INVESTORS OF THE DECEMBER 29, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
AVTR
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN BAXTER TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN BAXTER BETWEEN FEBRUARY 23, 2022 AND OCOBER 29, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST BAXTER INTERNATIONAL INC. ("BAXTER" OR THE "COMPANY") (NYSE: BAX) AND REMINDS INVESTORS OF THE DECEMBER 15, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
BAX
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN STRIDE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN STRIDE BETWEEN OCTOBER 22, 2024 AND OCTOBER 28, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST STRIDE, INC. ("STRIDE" OR THE "COMPANY") (NYSE: LRN) AND REMINDS INVESTORS OF THE JANUARY 12, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
LRN
• Dec. 7, 2025
CAMBRIDGE, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- PRIME MEDICINE, INC. (NASDAQ: PRME), A BIOTECHNOLOGY COMPANY COMMITTED TO DELIVERING A NEW CLASS OF DIFFERENTIATED ONE-TIME CURATIVE GENETIC THERAPIES, TODAY ANNOUNCED THE PUBLICATION OF PHASE 1/2 CLINICAL DATA WITH PM359, THE COMPANY'S INVESTIGATIONAL AUTOLOGOUS HEMATOPOIETIC STEM CELL PRODUCT FOR P47PHOX CHRONIC GRANULOMATOUS DISEASE (CGD) IN THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM). THE DATA WILL ALSO BE PRESENTED IN A POSTER SESSION AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, DECEMBER 6-9, 2025 IN ORLANDO, FLORIDA.
PRME
• Dec. 7, 2025
FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN BLUE OWL TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN BLUE OWL BETWEEN FEBRUARY 6, 2025 AND NOVEMBER 16, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST BLUE OWL CAPITAL INC. ("BLUE OWL" OR THE "COMPANY") (NYSE: OWL) AND REMINDS INVESTORS OF THE FEBRUARY 2, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.
OWL
• Dec. 7, 2025
SANTA MONICA, CALIF.--(BUSINESS WIRE)--KITE, A GILEAD COMPANY (NASDAQ: GILD), PRESENTED A NEW ANALYSIS TODAY DEMONSTRATING THAT SECOND-LINE YESCARTA® (AXICABTAGENE CILOLEUCEL) THERAPY OFFERS CONSISTENT BENEFITS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL), EVEN AMONG THOSE INELIGIBLE FOR THE PREVIOUS STANDARD OF CARE, HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AN AUTOLOGOUS STEM CELL TRANSPLANT (ASCT). RESULTS WERE SHARED FROM THE COMBINED ANALYSIS OF FOUR-YEAR DATA FROM THE LA.
GILD
• Dec. 7, 2025
AUSTIN, DEC. 07, 2025 (GLOBE NEWSWIRE) -- US STORMWATER MANAGEMENT MARKET SIZE AND GROWTH INSIGHTS: ACCORDING TO THE SNS INSIDER,"THE U. S. STORMWATER MANAGEMENT MARKET SIZE WAS USD 8. 25 BILLION IN 2025E AND IS PROJECTED TO GROW AT A CAGR OF 7.
• Dec. 7, 2025
- COMBINATION OF EVORPACEPT PLUS RITUXIMAB AND LENALIDOMIDE (R 2 ) GENERATED COMPLETE RESPONSES (CR) IN 92% OF PATIENTS WITH UNTREATED INDOLENT NON-HODGKIN LYMPHOMA (INHL) COMPARING FAVORABLY TO AN APPROXIMATE 50% HISTORICAL CR RATE FOR R 2 ALONE
ALX
• Dec. 7, 2025
- INOBRODIB IN COMBINATION WITH POMALIDOMIDE + DEXAMETHASONE (INOPD) DEMONSTRATES STRONG CLINICAL EFFICACY AND A TOLERABLE SAFETY PROFILE IN HEAVILY
• Dec. 7, 2025
MEDIA RELEASE COPENHAGEN, DENMARK; DECEMBER 7, 2025 TRIAL DEMONSTRATED TREATMENT WITH FIXED DURATION EPKINLY PLUS RITUXIMAB AND LENALIDOMIDE (EPKINLY+ R 2 ) RESULTED IN STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTION IN THE RISK OF DISEASE PROGRESSION OR DEATH AND OVERALL RESPONSE COMPARED TO R 2 ALONE EPKINLY + R 2 WAS RECENTLY APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION AS THE FIRST AND ONLY BISPECIFIC-BASED THERAPY FOR FOLLICULAR LYMPHOMA IN THE SECOND-LINE SETTING RESULTS OF EPCORE FL-1 SIMULTANEOUSLY PUBLISHED IN THE LANCET GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED PRIMARY DATA FROM THE PIVOTAL PHASE 3 EPCORE ® FL-1 STUDY EVALUATING FIXED DURATION EPKINLY ® (EPCORITAMAB-BYSP) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (EPKINLY + R 2 ) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). THE STUDY SHOWED THAT TREATMENT WITH EPKINLY + R2 REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 79% (HR 0.21, 95% CI: 0.14-0.31, P
GMAB
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALEXANDRIA REAL ESTATE EQUITIES, INC. (NYSE: ARE) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER A SIGNIFICANT STOCK DROP RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ALEXANDRIA REAL ESTATE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/ALEXANDRIA-REAL-ESTATE-CLASS-ACTION-LAWSUIT.
ARE
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST INSPIRE MEDICAL SYSTEMS, INC. (NYSE: INSP) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER A SIGNIFICANT STOCK DROP RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN INSPIRE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/INSPIRE-MEDICAL-SYSTEMS-INC-CLASS-ACTION-LAWSUIT.
INSP
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST STRIDE, INC. (NYSE: LRN) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER SIGNIFICANT STOCK DROPS RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN STRIDE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/STRIDE-INC-CLASS-ACTION-LAWSUIT.
LRN
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES AN INVESTIGATION INTO JEFFERIES FINANCIAL GROUP INC. (NYSE: JEF) AND POINT BONITA CAPITAL FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS AFTER SEC PROBE IS REVEALED. IF YOU INVESTED IN JEFFERIES OR POINT BONITA, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/JEFFERIES-FINANCIAL-GROUP-INC-CLASS-ACTION.
JEF
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST SYNOPSYS, INC. (NASDAQ: SNPS) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER A SIGNIFICANT STOCK DROP RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN SYNOPSYS, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/SYNOPSYS-INC-CLASS-ACTION-LAWSUIT.
SNPS
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST FREEPORT-MCMORAN INC. (NYSE: FCX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER SIGNIFICANT STOCK DROPS RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN FREEPORT, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/FREEPORT-MCMORAN-INC-CLASS-ACTION-LAWSUIT.
FCX
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST CARMAX, INC. (NYSE: KMX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER A SIGNIFICANT STOCK DROP RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN CARMAX, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/CARMAX-INC-CLASS-ACTION-LAWSUIT.
KMX
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN MOONLAKE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/MOONLAKE-IMMUNOTHERAPEUTICS-CLASS-ACTION-LAWSUIT.
MLTX
• Dec. 7, 2025
NEW YORK, DEC. 07, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST JAMES HARDIE INDUSTRIES PLC (NYSE: JHX) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR SECURITIES FRAUD AFTER A SIGNIFICANT STOCK DROP RESULTING FROM THE POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN JAMES HARDIE, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/JAMES-HARDIE-INDUSTRIES-CLASS-ACTION-LAWSUIT.
JHX
• Dec. 7, 2025
ZURICH-SCHLIEREN, SWITZERLAND AND CONCORD, MASS., DEC. 07, 2025 (GLOBE NEWSWIRE) -- AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR MOLECULAR PARTNERS AG (SIX: MOLN; NASDAQ: MOLN), A CLINICAL-STAGE BIOTECH COMPANY DEVELOPING A NEW CLASS OF CUSTOM-BUILT PROTEIN DRUGS KNOWN AS DARPIN THERAPEUTICS (“MOLECULAR PARTNERS” OR THE “COMPANY”), HAS TODAY ANNOUNCED IT WILL PRESENT UPDATED DATA FROM A PHASE 1/2A TRIAL OF THE MULTISPECIFIC T-CELL ENGAGER MP0533 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN A POSTER AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION, TAKING PLACE DECEMBER 6-9, 2025, IN ORLANDO, FLORIDA.
PGPHF
• Dec. 7, 2025
NEW YORK, NEW YORK--(NEWSFILE CORP. - DECEMBER 7, 2025) - FOR THE FIRST TIME, CREDITORS CAN RECOVER DEBTOR ARREARS THROUGH
• Dec. 7, 2025
LONDON, UNITED KINGDOM--(NEWSFILE CORP. - DECEMBER 7, 2025) - UK-BASED E-COMMERCE PLATFORM DEDICATED TO BRITAIN'S GREATEST FIZZ, ENGLISHSPARKLINGWINES.COM, HAS PRESENTED
• Dec. 7, 2025
SHANGHAI , DEC. 7, 2025 /PRNEWSWIRE/ -- CARSGEN THERAPEUTICS HOLDINGS LIMITED (STOCK CODE: 2171.HK), A COMPANY FOCUSED ON DEVELOPING INNOVATIVE CAR T-CELL THERAPIES, ANNOUNCED TODAY ANNOUNCED WITH GREAT PLEASURE THAT ITS INDEPENDENTLY DEVELOPED FULLY HUMAN BCMA-TARGETED CAR-T PRODUCT, ZEVORCABTAGENE AUTOLEUCEL (ZEVOR-CEL, R&D CODE: CT053), HAS BEEN INCLUDED IN CHINA'S COMMERCIAL HEALTH INSURANCE INNOVATIVE DRUG CATALOGUE (2025) (REFERRED TO AS THE "INNOVATIVE DRUG CATALOGUE") FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA. THE INNOVATIVE DRUG CATALOGUE WAS RELEASED TODAY AT A PRESS CONFERENCE HELD BY THE NATIONAL HEALTHCARE SECURITY ADMINISTRATION (NHSA) IN GUANGZHOU.
CRTHF
• Dec. 7, 2025
